Live birth after fresh versus frozen single blastocyst transfer: a randomized controlled trial

Conditions

Infertility

Jia Lin, Junzhao Zhao, Guimin Hao, Jichun Tan, Ye Pan et al. (9 authors)

Frontiers in Medicine2020-08-2825 citations

10.3389/fmed.2020.00338

Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial.

Wei D, Liu JY, Sun Y, Shi Y, Zhang B, Liu JQ, Tan J, Liang X, Cao Y, Wang Z, Qin Y, Zhao H, Zhou Y, Ren H, Hao G, Ling X, Zhao J, Zhang Y, Qi X, Zhang L, Deng X, Chen X, Zhu Y, Wang X, Tian LF, Lv Q, Ma X, Zhang H, Legro RS, Chen ZJ.

2019-02-28326 citations

10.1016/s0140-6736(18)32843-5

Live birth after fresh versus frozen single blastocyst transfer (Frefro-blastocyst): study protocol for a randomized controlled trial.

Wei D, Sun Y, Liu J, Liang X, Zhu Y, Shi Y, Chen ZJ.

2017-06-059 citations

10.1186/s13063-017-1993-5

Interventions

Fresh embryo transfer group:single fresh blastocyst transfer

Frozen embryo transfer group:freeze all embryo and single thawed blastocyst transfer

Eligibility

Sex/Gender

Female

Age

20 Years to 34 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 20 to 35 years; 2. Women with regular menses (defined as spontaneous cycle length 21 to 35 days); 3. Women who undergo their first cycle of IVF or ICSI; 4. Women with the number of transferrable D3 embryos?4.

Exclusion criteria

Exclusion criteria: 1. Women who have been diagnosed with congenital or acquired uterine abnormalities such as uterine malformation (uterus unicornis, septate uterus or duplex uterus), adenomyosis, submucous myoma or intrauterine adhesion; 2. Women who have been planned to undergo preimplantation genetic diagnosis (PGD) /preimplantation genetic screening (PGS); 3. Women who have been planned to undergoing frozen embryo transfer before randomization such as who are scheduled to treat hydrosalpinx, who have elevated progesterone during controlled ovarian hyperstimulation (COH) or who have high risk of severe ovarian hyperstimulation syndrome (OHSS); 4. Women with medical conditions that contraindicate assisted reproductive technology and/or pregnancy, such as uncontrolled hypertension or known symptomatic heart disease; poorly controlled type 1 or type 2 diabetes mellitus; undiagnosed liver disease or dysfunction (based on serum liver enzyme test results); renal disease or abnormal serum renal function; severe anemia; history of deep venous thrombosis, pulmonary embolus or cerebrovascular accident; history of (or suspected) cervical carcinoma, endometrial carcinoma or breast carcinoma.

Design outcomes

Primary

Measure	Time frame
Singleton live birth rate;	—

Secondary

Measure	Time frame
conception rate;clinical pregnancy rate;ongoing pregnancy rate;pregnancy loss rate;live birth rate;birth weight;Incidence of moderate and severe OHSS;Incidence of ectopic preganncy;Incidence of pregnancy and perinatal complications;Incidence of neonatal complications;Incidence of other adverse events;	—

Countries

China

Contacts

Public ContactZi-Jiang Chen

Center for Reproductive Medicine, Shandong University

chenzijiang59@gmail.com+86 0531-85861173

Outcome results

None listed